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Objective: Skin-sparing mastectomy (SSM) with immediate heterologous reconstruc-
tion is a safe oncological option in surgical therapy of early breast cancer. Permacol® is 
an acellular dermal matrix (ADM) placed between the implant and the skin to improve 
lower pole projection and implant coverage. The aim of our study was to evaluate the 
outcome with a focus on patient satisfaction after 6 months and to analyze physical 
changes of ADM.
Methods: 10 patients who underwent SSM with Permacol® were analyzed retrospec-
tively. All patients were followed using a satisfaction questionnaire and an ultrasound 
evaluation of the tissue thickness of the pectoralis muscle and the Permacol®.
results: No intraoperative complications were observed. One patient required removal 
of the implant for necrosis after 3 months. Half of the patients underwent secondary cor-
rective surgery. A statistically significant thinning of the pectoralis muscle was observed, 
compared to the thickening of the Permacol®. A majority of the patients were satisfied 
with the operation, and we found a correlation between lower body mass index and 
patient satisfaction.
conclusion: In our small case series Permacol®-assisted immediate reconstruction is 
shown to be an option for selected cases. Physical changes of Permacol® result in a 
symmetrical coverage of the implant, which may improve cosmetic outcome.
Keywords: breast cancer, Permacol®, acellular dermal matrices, heterologous immediate breast reconstruction, 
skin-sparing mastectomy
FigUre 1 | intraoperative placement of the implant and Permacol®.
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inTrODUcTiOn
Breast cancer is the most common cancer in women. In 
Switzerland, about 5,500 women are diagnosed with breast cancer 
each year (1).
In early breast cancer or in the case of precancerous lesions, 
skin-sparing mastectomy (SSM) is nowadays an established 
surgical technique. By conserving the skin envelope and combin-
ing this with immediate reconstruction, SSM provides excellent 
cosmetic results. Furthermore, the oncological safety of SSM 
has been demonstrated, with recurrence rates being similar to 
classical mastectomy (2). In the last decades, mastectomy pro-
cedures and immediate reconstruction are increasing due to the 
awareness to provide risk-reducing mastectomy, better cosmetic 
results, and the patients’ aim (3).
Nevertheless, the complication rate in SSM followed by 
reconstruction remains an important issue. Adverse outcomes, 
including skin necrosis, dislocation of the implant, and, capsular 
contracture, occur in up to 14% of patients (4).
Acellular dermal matrices (ADMs) have been available since 
the early 1990s. Initially used for abdominal hernia repair and 
burn treatment, their utilization has expanded to breast recon-
struction. Various types of ADMs exist, derived either from 
human cadaveric dermis (e.g., AlloDerm® and FlexHD®) or from 
porcine dermis (e.g., Permacol® and Strattice®). In an elaborate 
process, cellular components and genetic material are removed; 
the result is a sterile mesh composed of collagen types I and III 
and elastin. Histological studies have shown that ADMs become 
repopulated by host tissue and neovascularized within several 
days after implantation (5). In a comparative study that looked 
at the physical characteristics of different ADMs, Permacol® 
showed the highest values of maximum loads, stiffness, and 
tensile strength (6).
Acellular dermal matrices are used in one- and two-stage 
reconstructions. After SSM and placement of the prosthesis, the 
acellular matrix is sutured to the lower border of the pectoralis 
muscle to cover the lower pole of the implant. Lower pole pro-
jection and the soft tissue coverage are thereby improved. This 
approach results in a good cosmetic outcome with an acceptable 
complication rate (7).
Despite a lack of randomized controlled studies to analyze 
outcomes of breast reconstruction with ADMs, 84.2% of mem-
bers of the American Society of Plastic Surgeons reported in a 
survey in 2015 that they used ADMs in breast reconstructions 
routinely (8).
The aim of the current study is to evaluate the outcome of SSM 
followed by Permacol®-assisted implant-based immediate recon-
struction, with a focus on the physical changes of Permacol®, 
cosmetic results, and patient satisfaction.
MaTerials anD MeThODs
The first 10 patients to undergo SSM and ADM-assisted immedi-
ate breast reconstruction for invasive or in situ breast carcinoma, 
between July 2010 and April 2011 in our certified breast cancer 
at the University Hospital of Berne, were analyzed in the current 
study.
Ethical approval from the local ethics committee was obtained, 
and all patients gave informed consent.
Skin-sparing mastectomy was performed by lateral axillary 
incision, conserving a maximum of 5  mm of subcutaneous 
tissue. Resection of breast tissue always included the pectoralis 
fascia. The decision on nipple areola complex (NAC) preserva-
tion was based on the criteria reported by Gerber et al. (9). NAC 
involvement was excluded by intraoperative frozen section of 
a retroareolar disk. The implant was placed under the inferior 
part of the pectoralis muscle. A Permacol® sheet measuring 
50 mm × 100 mm × 1.5 mm was sutured to the lower brim of 
the pectoralis muscle, creating a cup for the implant (Figure 1). 
The dermis was closed with an absorbable intradermal suture. In 
all patients at least one drain was placed. Antibiotic therapy was 
administered until ablation of the drains.
Operation data including duration of surgery, blood loss, 
implant size, and intra- and postoperative complications were 
obtained from patient charts.
To evaluate the physical changes of Permacol® after implanta-
tion, standardized measurements of the thickness of subcutane-
ous soft tissue were performed at 1  week and 6  months after 
operation. The thickness was measured in a horizontal axis at 
two predefined positions, caudal and cranial of the matrix. These 
values were then compared to the thickness of the pectoralis 
muscle at two specific areas (Figure 2).
In the follow-up after 6 months, all patients were questioned 
using a standard patient-satisfaction questionnaire. The ques-
tionnaire consisted of six questions on satisfaction with regard 
to the outcome and the postoperative experience (Table 1). The 
answers were scaled using scores from 1 to 5 (1 = strongly agree, 
2 = agree, 3 = undecided, 4 = disagree, and 5 = strongly disagree).
Long-term follow-up was evaluated by regular check-ups in 
our breast center.
Statistical analysis was performed using GraphPad InStat 
Version 3.10. Quantitative variables were tested by the Student’s 
t-test. Also, p < 0.05 was considered statistically significant.
resUlTs
The indications for SSM with immediate reconstruction were 
multicentric carcinoma (n = 6), diffuse ductal carcinoma in situ 
TaBle 2 | surgery data.
Patient Blood loss (ml) Duration (min) implant size (mm)
1 200 120 165
2 200 120 295
3 200 120 335
4 400 90 420
5 200 160 390
6 500 120 240
7 10 45 220
8 300 120 180
9 400 120 210
10 200 120 285
Mean 261 113 274
TaBle 1 | Postoperative questionnaire.
1. Is the size and the shape of my breast the same as before the surgery?
2. Are my reconstructed breasts soft?
3. Was corrective surgery necessary?
4. Am I satisfied with the results?
5. If I had the knowledge that I have now after the operation, would I still decide 
for the breast reconstruction as I did so before having surgery?
6. Would I recommend this surgery to a friend?
FigUre 2 | Defined locations of thickness measurements of the 
Permacol® and pectoral muscle.
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(DCIS) (n =  3), and carcinoma with extensive DCIS (n =  1). 
The mean age of the patients was 50.9  years (37–64  years) at 
the moment of operation. The average BMI was 21.1  kg/m2 
(17.6–26.5  kg/m2). Two patients had a history of smoking (7.5 
and 14 pack years), and one had a past medical history of diabetes 
mellitus. One patient had a previous tumorectomy with positive 
resection margins.
Drains were removed after a median of 5.8 days (2–9 days). 
In all patients, prophylactic antibiotic therapy was administered 
until ablation of the drains.
No intraoperative complications were observed. The surgical 
data are summarized in Table  2. Two patients required surgi-
cal revision for hematoma, 2 and 4 days after initial surgery. In 
one patient, the implant had to be removed due to severe skin 
necrosis 3 months after initial operation; the patient smoked and 
had previous ipsilateral breast surgery. One patient developed 
capsule fibrosis after 6  months and received an autologous 
reconstruction.
The long-term follow-up with a median of 45.7 months (19–
60 months) was uneventful in 5 out of 10 patients. One patient 
required minor corrective surgery. Three patients developed 
severe capsular contracture and received implant explanation 
followed by autologous reconstruction 7, 19, and 26 months after 
initial surgery. One patient was operated recently in response to 
suspicion of implant rupture and received reconstruction with a 
DIEP-Flap.
We also analyzed the physical changes of Permacol®. We found 
a reduction in thickness of the pectoralis muscle from 9.8 to 
4.1 mm (cranial) (p< = 0.03) and from 8.8 to 4.5 mm (caudal) 
(p < 0.03).
The thickness of Permacol® increased from 1.5 to 1.9  mm 
(cranial) (p = 0.064) and from 1.5 to 2.0 mm (caudal) (p = 0.051).
We evaluated the patient’s satisfaction 6 months postopera-
tively via a questionnaire. The majority (n = 8) of the patients 
were satisfied with the similarity of the breast shape pre- and 
postoperatively. Only one patient noted a considerable change 
after capsule fibrosis. Most patients were indifferent when 
responding to the question on whether their reconstructed 
breast was soft: seven gave a score of 3–4. None of the patients 
had their implants removed because of infection. Most patients 
(n = 7) were satisfied with the results of the surgery (scores of 
1 and 2), with only two patients answering somewhat negatively 
(scores of 3 and 4). Six patients would do this surgery again. Six 
patients would recommend this surgery to a friend; only one 
patient responded that she would absolutely not recommend 
the surgery.
We analyzed also the correlation between BMI and patients 
satisfaction and observed that the satisfaction level decreased 
with increasing BMI (Figure 3).
DiscUssiOn
The major finding of our study is that SSM followed by immediate 
Permacol®-assisted heterologous breast reconstruction is a feasi-
ble operation with no intraoperative complications for patients 
with breast cancer. Furthermore, we could observe a significant 
increase in the thickness of the Permacol® sheet over the implant 
and at the same time a significant decrease in the thickness of the 
pectoralis muscle. This results in a symmetrical surface over the 
implant.
Although some advantages of Permacol® were observed 
including the physical changes and lower costs, the disadvan-
tages as low elasticity and the high percentage of required cor-
rective surgery in our cohort finally led us to prefer alternative 
matrices.
To the best of our knowledge, there are only few studies to 
date that analyze the physical changes of ADMs in vivo. O’Brien 
examined histological and mechanical results of an explanted 
FigUre 3 | correlation between BMi and patient’s satisfaction.
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piece of Permacol® 2  years after abdominal wall repair; he 
found an increased breaking strength due to the integration of 
human collagen and elastin, without any sign of inflammation 
(10). In 2011, Mulier demonstrated in an experiment on 89 rats 
that Permacol® maintained thickness and showed greater tensile 
strength than Strattice®, which decreased significantly in thick-
ness starting at 3 months (11). Further studies must be conducted 
to deepen the understanding of mechanical and physical changes 
of ADMs in vivo.
The use of ADMs in breast reconstruction has become very 
popular in the last few years. Whereas in 2010, 50% of plastic 
surgeons reported using ADMs in their daily practice for breast 
reconstruction, and in 2015, 84.2% of plastic surgeons in the 
United States reported using it routinely (8, 12). However, the 
literature indicates that there is a lack of randomized controlled 
trials evaluating the outcome of ADM-assisted breast reconstruc-
tion. The data are poor concerning esthetic results and patient 
satisfaction.
A recent review and meta-analysis concluded that the use of 
ADMs appeared to enhance the risk of infection, seroma, and 
necrosis, but the risk of serious complications and overall mortal-
ity might not be increased (13). The rate of capsular contracture 
seems to be reduced by the use of ADMs (14).
In our study cohort, follow-up showed a need for corrective 
surgery in about half of the patients. Two patients required 
revision in the immediate postoperative period, and one 
patient suffered from necrosis 3  months after the operation. 
The long-term follow-up revealed that four patients developed 
capsular contracture, which necessitated implant removal in a 
mean time of 27 months (7–56). This may be partially due to a 
learning curve, as we analyzed in this study the first 10 patients 
operated by ADM-assisted breast reconstruction in our center. 
It is however a well-known problem in breast reconstructions 
that follow-up operations are needed to optimize the esthetic 
outcome. This must be emphasized in preoperative counseling. 
One important factor in choosing the appropriate reconstruc-
tive surgery is patient selection. We noticed a direct correlation 
between BMI and patient satisfaction. This finding is consistent 
with other authors’ showing a correlation between higher BMI 
and wound infection, reoperations, and major complication rates 
(15, 16). Other risk factors identified are smoking and previous 
surgery or adjuvant radiotherapy (17).
These aspects might help us identify the“ideal”patients for 
reconstructive breast surgery with Permacol®.
However, the follow-up questionnaire at 6 months postopera-
tively revealed that the majority were satisfied with the outcome 
and would recommend the operation to a friend. We are con-
vinced of the importance of preoperative counseling including 
explanation of potential complications but also of possible benefit 
of the use of ADMs in breast reconstruction; furthermore, the 
careful patient selection is crucial.
cOnclUsiOn
In our small case series, the SSM using Permacol® for immediate 
heterologous breast reconstruction is shown to be an option for 
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selected cases. Physical changes of Permacol® result in a sym-
metrical coverage of the implant, which may improve cosmetic 
outcome. We observed an acceptable patient-satisfaction rate. 
This study further showed good feasibility and no severe direct 
postoperative complications. A careful patient selection, accord-
ing to BMI and other risk factors, has to be performed in order 
to reduce the number of follow-up operations.
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